^
CANCER:

Lung Cancer

Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
No biomarker
Small Cell Lung Cancer
lurbinectedin
Sensitive
:
A1
Pharmamar Press Release - 4 days - (New A1)
EGFR T263P + EGFR L858R + MET amplification
Non Small Cell Lung Cancer
erlotinib + capmatinib
Sensitive
:
C4
Front Oncol - 4 days - (New C4)
KRAS mutation + KMT2C mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
Onco Targets Ther - 6 days - (New C3)
STRN-ALK fusion
Lung Adenocarcinoma
ensartinib
Sensitive
:
C4
Curr Oncol - 6 days - (New C4)
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
toripalimab
Sensitive
:
A1
GlobeNewswire - 1 week - (New A1)
EPHA5 mutation
Non Small Cell Lung Cancer
atezolizumab
Resistant
:
C3
BMC Pulm Med - 1 week - (New C3)
CCDC85A-ALK fusion
Lung Adenocarcinoma
alectinib
Sensitive
:
C4
J Cell Mol Med - 1 week - (New C4)
EGFR wild-type
Non Small Cell Lung Cancer
atezolizumab
Sensitive
:
C3
Nat Med - 2 weeks - (New C3)
ALK rearrangement + PD-L1 overepxression
Non Small Cell Lung Cancer
ALK inhibitor
Resistant
:
C3
Front Immunol - 2 weeks - (New C3)
ALK rearrangement + CTLA4 overexpression
Non Small Cell Lung Cancer
ALK inhibitor
Resistant
:
C3
Front Immunol - 2 weeks - (New C3)
ALK wild-type
Non Small Cell Lung Cancer
atezolizumab
Sensitive
:
C3
Nat Med - 2 weeks - (New C3)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression
Lung Adenocarcinoma
pembrolizumab
Sensitive
:
C4
Lung Cancer - 2 weeks - (New C4)
CD74-NRG1 fusion + EGFR mutation + HER-2 mutation
Lung Adenocarcinoma
afatinib + pyrotinib
Sensitive
:
C4
Thorac Cancer - 2 weeks - (New C4)
STK11 mutation
Lung Non-Squamous Non-Small Cell Cancer
durvalumab + CP-675206
Resistant
:
B
ESMO 2022 - 3 weeks - (New B)
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
EGFR wild-type
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
B
Cancer Med - 3 weeks - (New B)
ALK wild-type
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
B
Cancer Med - 3 weeks - (New B)
KRAS mutation
Non Small Cell Lung Cancer
durvalumab + CP-675206
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
KEAP1 mutation
Non Small Cell Lung Cancer
durvalumab + CP-675206
Sensitive
:
B
ESMO 2022 - 3 weeks - (New B)
PD-L1 expression
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ROS1 rearrangement
Non Small Cell Lung Cancer
brigatinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
BRAF mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-L1 expression
Non Small Cell Lung Cancer
PD1 inhibitor
Sensitive
:
C3
Cancers (Basel) - 3 weeks - (New C3)
PD-L1 expression
Non Small Cell Lung Cancer
PD-L1 inhibitor
Sensitive
:
C3
Cancers (Basel) - 3 weeks - (New C3)
EGFR exon 20 mutation
Non Small Cell Lung Cancer
afatinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-L1 overexpression
Non Small Cell Lung Cancer
sintilimab
Sensitive
:
C3
BMC Cancer - 3 weeks - (New C3)
MET amplification + EGFR mutation
Non Small Cell Lung Cancer
osimertinib + tepotinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
RB1 wild-type
Small Cell Lung Cancer
nivolumab
Sensitive
:
C3
JCO Precis Oncol - 3 weeks - (New C3)
HER-2 amplification
Lung Cancer
trastuzumab + pertuzumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR L858R
Non Small Cell Lung Cancer
KN046
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR exon 19 deletion
Non Small Cell Lung Cancer
KN046
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR mutation
Non Small Cell Lung Cancer
BPI-7711
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CCDC6-RET fusion
Non Small Cell Lung Cancer
pralsetinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation + MET overexpression
Non Small Cell Lung Cancer
capmatinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation + ALK wild-type
Non Small Cell Lung Cancer
capmatinib + PDR001
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation + EGFR wild-type
Non Small Cell Lung Cancer
capmatinib + PDR001
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
HER-2 G778_P780dup
Non Small Cell Lung Cancer
HM 78136B
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS G12D
Non Small Cell Lung Cancer
nivolumab + rigosertib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C
Non Small Cell Lung Cancer
nivolumab + rigosertib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS G12V
Non Small Cell Lung Cancer
nivolumab + rigosertib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KEAP1 mutation
Non Small Cell Lung Cancer
pembrolizumab + ramucirumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
STK11 mutation
Non Small Cell Lung Cancer
pembrolizumab + ramucirumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KIT mutation
Non Small Cell Lung Cancer
Immunotherapy
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET exon 14 mutation
Non Small Cell Lung Cancer
CKD-702
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR mutation + PD-L1 expression
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EML4-ALK fusion + ALK positive
Non Small Cell Lung Cancer
brigatinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
ALK rearrangement
Lung Non-Squamous Non-Small Cell Cancer
alectinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C + ATM wild-type
Non Small Cell Lung Cancer
KRAS inhibitor
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
KRAS G12C + SMARCA4 wild-type
Non Small Cell Lung Cancer
KRAS inhibitor
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
RET positive + SMARCA4 mutation
Non Small Cell Lung Cancer
RET inhibitor
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
RET positive + KRAS G12V
Non Small Cell Lung Cancer
RET inhibitor
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR exon 20 insertion + TP53 mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET amplification + MET overexpression
Non Small Cell Lung Cancer
REGN5093
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET overexpression
Non Small Cell Lung Cancer
REGN5093
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
CYP4B1 expression
Lung Cancer
Immunotherapy
Resistant
:
C3
ESMO 2022 - 3 weeks - (New C3)
CLEC3B overexpression
Non Small Cell Lung Cancer
Immunotherapy
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
EGFR exon 18 mutation + EGFR exon 21 mutation
Non Small Cell Lung Cancer
afatinib
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
PD-L1 underexpression
Lung Non-Squamous Non-Small Cell Cancer
MEDI5752
Sensitive
:
C3
ESMO 2022 - 3 weeks - (New C3)
MET amplification + EGFR mutation
Non Small Cell Lung Cancer
lazertinib + ABN401
Sensitive
:
D
ESMO 2022 - 3 weeks - (New D)
EGFR C797S + EGFR T790M + EGFR exon 19 deletion
Non Small Cell Lung Cancer
JIN-A02
Sensitive
:
D
ESMO 2022 - 3 weeks - (New D)
EGFR C797S + EGFR T790M + EGFR L858R
Non Small Cell Lung Cancer
JIN-A02
Sensitive
:
D
ESMO 2022 - 3 weeks - (New D)
EGFR mutation + CDCA3 underexpression
Non Small Cell Lung Cancer
osimertinib
Resistant
:
D
ESMO 2022 - 3 weeks - (New D)
EGFR mutation + CDCA3 underexpression
Non Small Cell Lung Cancer
erlotinib
Resistant
:
D
ESMO 2022 - 3 weeks - (New D)
EGFR mutation
Non Small Cell Lung Cancer
osimertinib
Sensitive
:
A1
AstraZeneca Press Release - 4 weeks - (New A1)
EGFR wild-type
Lung Non-Small Cell Squamous Cancer
cemiplimab
Sensitive
:
B
Nat Med - 4 weeks - (New B)
EGFR wild-type
Lung Non-Squamous Non-Small Cell Cancer
cemiplimab
Sensitive
:
B
Nat Med - 4 weeks - (New B)
ROS1 wild-type
Lung Non-Small Cell Squamous Cancer
cemiplimab
Sensitive
:
B
Nat Med - 4 weeks - (New B)
ROS1 wild-type
Lung Non-Squamous Non-Small Cell Cancer
cemiplimab
Sensitive
:
B
Nat Med - 4 weeks - (New B)
ALK wild-type
Lung Non-Squamous Non-Small Cell Cancer
cemiplimab
Sensitive
:
B
Nat Med - 4 weeks - (New B)
ALK wild-type
Lung Non-Small Cell Squamous Cancer
cemiplimab
Sensitive
:
B
Nat Med - 4 weeks - (New B)
EGFR L858R
Non Small Cell Lung Cancer
EGFR inhibitor
Sensitive
:
C3
J Cancer Res Clin Oncol - 4 weeks - (New C3)
HER-2 amplification
Non Small Cell Lung Cancer
rivoceranib + pyrotinib
Sensitive
:
C3
BMC Med - 4 weeks - (New C3)
EML4-ALK variant 1
Non Small Cell Lung Cancer
crizotinib
Sensitive
:
C3
Eur J Cancer - 4 weeks - (New C3)
ALK mutation
Non Small Cell Lung Cancer
ALK inhibitor
Sensitive
:
C3
Medicine (Baltimore) - 4 weeks - (New C3)
BRAF mutation
Non Small Cell Lung Cancer
trametinib + dabrafenib
Sensitive
:
C3
ISPOR-EU 2022 - 4 weeks - (New C3)
EGFR mutation + UBXN11 mutation
Non Small Cell Lung Cancer
erlotinib
Resistant
:
C3
J Clin Oncol - 4 weeks - (New C3)
EGFR T790M
Non Small Cell Lung Cancer
BPI-7711
Sensitive
:
C3
J Thorac Oncol - 4 weeks - (New C3)
EGFR L858R
Non Small Cell Lung Cancer
Angiogenesis inhibitor
Sensitive
:
C3
Sci Rep - 4 weeks - (New C3)
HER-2 mutation
Non Small Cell Lung Cancer
rivoceranib + pyrotinib
Sensitive
:
C3
BMC Med - 4 weeks - (New C3)
SLC8A1-ALK fusion
Lung Adenocarcinoma
ceritinib
Sensitive
:
C4
Medicine (Baltimore) - 4 weeks - (New C4)
EGFR exon 21 mutation
Lung Adenocarcinoma
dacomitinib
Sensitive
:
C4
Medicine (Baltimore) - 4 weeks - (New C4)
PD-L1 expression
Non Small Cell Lung Cancer
atezolizumab
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
afatinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
osimertinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
ramucirumab
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
lorlatinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
gefitinib
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
afatinib
Sensitive
:
A1
EGFR T790M
Non Small Cell Lung Cancer
osimertinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
durvalumab
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
alectinib
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
pembrolizumab
Sensitive
:
A1
ALK fusion
Non Small Cell Lung Cancer
brigatinib
Sensitive
:
A1
KRAS G12C
Non Small Cell Lung Cancer
sotorasib
Sensitive
:
A1
PD-L1 expression
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
osimertinib
Sensitive
:
A1
ALK positive
Non Small Cell Lung Cancer
brigatinib
Sensitive
:
A1
ROS1 fusion
Non Small Cell Lung Cancer
entrectinib
Sensitive
:
A1
MET exon 14 mutation
Non Small Cell Lung Cancer
tepotinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
bevacizumab
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
dacomitinib
Sensitive
:
A1
No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive
:
A1
EGFR T790M
Non Small Cell Lung Cancer
lazertinib
Sensitive
:
A1
EGFR exon 19 deletion
Non Small Cell Lung Cancer
dacomitinib
Sensitive
:
A1
MET exon 14 mutation
Non Small Cell Lung Cancer
capmatinib
Sensitive
:
A1
PD-L1 overexpression
Non Small Cell Lung Cancer
cemiplimab
Sensitive
:
A1
RET fusion
Non Small Cell Lung Cancer
pralsetinib
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
cisplatin + pemetrexed
Sensitive
:
A1
EGFR mutation
Non Small Cell Lung Cancer
gefitinib
Sensitive
:
A1
EGFR L858R
Non Small Cell Lung Cancer
gefitinib
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pemetrexed
Sensitive
:
A1